ClinicalTrials.gg
RecruitingNCT01532791Updated Jan 23, 2026

Natural History Study - Mitochondrial Disease

An observational study in MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Columbia University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2004; still recruiting 22 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in MELAS Syndrome with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. MELAS Syndrome · United States.

Started
2004
the only one that year
Observational
5 of 21
3 open now
Registered
7th of 21
by date
Lead sponsor
3 of 21
Columbia University

Among the 21 studies in MELAS Syndrome with a site in United States, this one is the only one that started in 2004, is one of 5 observational ones, and was the 7th registered.

MELAS Syndrome

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

Browse MELAS Syndrome studies →

Open to participants now

6 of the 21 studies in MELAS Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 MELAS Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 4 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in MELAS Syndrome with a site in United States, or all of them as a file.
02

Study summary

Carriers of the m.3242A>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. The focus of the current work is to evaluate known mutation carriers of the m.3243A>G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement for participation). Paternal relatives will serve as controls. This study involves no treatment.

Read the detailed description

The purpose of this study is to investigate the neurological and biochemical consequences of the m.3243 A>G mutation. Mitochondria are the powerhouses of the cell and are controlled by nuclear genetic material (DNA) and mitochondrial (mt) DNA. Mitochondrial DNA mutations impair mitochondrial function, and cause cellular energy failure. These mutations, when present in high abundance, cause neurological signs and symptoms that are clinically obvious. The investigators hypothesize that these mutations, when present in lesser abundance, will cause measurable alterations in the patient's neuropsychological profile and cerebral energy profile. This study does not involve any experimental or approved therapy. The investigators will evaluate the patient's condition with blood/urine tests, neurological exam, MRI/MRS, questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.

03

Conditions studied

  • MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier

Browse trials for

Keywords

  • MELAS
  • mitochondrial DNA mutation
  • mtDNA mutation
  • mitochondrial DNA
  • mitochondria
  • m.3243A>G mutation
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Carriers of the m.3243A>G mitochondrial DNA point mutation, and their maternal relatives (carrier status documentation not required.). All patients suspected of having an mtDNA point mutation regardless of age, health status, gender, race, or ethnicity will be evaluated. The minimal age of entry into the study will be 4 years or older. We will also evaluate controls (often these are married in relatives).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Known carrier of a the m.3243 A>G mitochondrial mutation, ,or Maternally related to someone who carries the m.3243A>G mitochondrial mutation.

A family member who is not maternally related to someone who carries the m.3243A>G mitochondrial mutation

Exclusion criteria

Exclusion Criteria:

  • Younger than 4 years of age
  • No confirmed m.3243 A>G mitochondrial DNA mutation in the family.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (estimated)
Biospecimen retention
None retained

Groups and cohorts

  • mtDNA mutation

    m.3243 A\>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included

  • Control

    controls (people not maternally related to mutation carriers) Preference is for married in relatives

06

What researchers measure

Primary outcomes

  1. MRI/MRS

    Evaluate structure and function in brain and muscle

    Time frame: 2-3 years

Secondary outcomes

  1. Biomarkers

    Evaluate various biomarkers of disease progression

    Time frame: 2-3 years

  2. Motor skills

    6 minute walk test to evaluate motor skills

    Time frame: 2-3 years

  3. Cognitive function

    Evaluate cognitive function through neuropsychological testing

    Time frame: 2-3 years

  4. Clinical symptoms

    Evaluate clinical symptoms through medical history questionnaires and physical exam

    Time frame: 2-3 years

  5. Mutation load

    Evaluate heteroplasmy through blood,urine and skin fibroblast evaluations

    Time frame: 2-3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Weiduschat N, Kaufmann P, Mao X, Engelstad KM, Hinton V, DiMauro S, De Vivo D, Shungu D. Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. Neurology. 2014 Mar 4;82(9):798-805. doi: 10.1212/WNL.0000000000000169. Epub 2014 Jan 29. PubMed 24477106 ↗
  • Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, Dimauro S, De Vivo DC. Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology. 2011 Nov 29;77(22):1965-71. doi: 10.1212/WNL.0b013e31823a0c7f. Epub 2011 Nov 16. PubMed 22094475 ↗
  • Mehrazin M, Shanske S, Kaufmann P, Wei Y, Coku J, Engelstad K, Naini A, De Vivo DC, DiMauro S. Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS. Am J Med Genet A. 2009 Feb 15;149A(4):584-7. doi: 10.1002/ajmg.a.32703. PubMed 19253345 ↗
  • Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, Koenigsberger DY, Pascual JM, Sano M, Hirano M, DiMauro S, Shungu DC, Mao X, De Vivo DC. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol. 2009 Jan;66(1):85-91. doi: 10.1001/archneurol.2008.526. PubMed 19139304 ↗

Individual participant data

Plan to share: Yes — When applicable, manuscript(s) regarding data will be submitted for publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2004 (actual). Primary completion is estimated for Jul 2026, 264 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2012
First posted
Feb 15, 2012
StartActual
Jul 2004
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01532791
Responsible party
Michio Hirano, MD (Professor of Neurology, Columbia University) — Principal investigator
First posted
Feb 15, 2012
Start date
Jul 2004
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 23, 2026

Study contacts

Kris Engelstad, MS
Contact
ke4@cumc.columbia.edu
2123056834
Michio Hirano, MD
principal investigator · mh29@cumc.columbia.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion